University Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, Germany; National Center for Tumor Diseases West, Campus Essen, and Research Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen, Germany.
University Hospital Zurich, Zurich, Switzerland.
Eur J Cancer. 2024 Jun;204:114073. doi: 10.1016/j.ejca.2024.114073. Epub 2024 Apr 24.
Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma. We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff).
577 patients with locally advanced unresectable or metastatic BRAF V600E/K-mutant melanoma who were treatment-naive or progressed after first-line immunotherapy were randomized 1:1:1 to encorafenib 450 mg once daily (QD) plus binimetinib 45 mg twice daily (BID) (n = 192), vemurafenib 960 mg BID (n = 191), or encorafenib monotherapy 300 mg QD (n = 194). No prior BRAF/MEK inhibitor was allowed.
Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively. Median melanoma-specific survival (95 % CI) was 36.8 months (27.7-51.5 months) in the encorafenib plus binimetinib arm and 19.3 months (14.8-25.9 months) in the vemurafenib arm. Thirty-four long-term responders (complete/partial response ongoing at 7 years) were identified across arms.
This is the longest follow-up from a phase III trial of BRAF/MEK inhibitor combination in BRAF V600E/K-mutant metastatic melanoma. Safety results were consistent with the known tolerability profile of encorafenib plus binimetinib. Results support the long-term efficacy and known safety of encorafenib plus binimetinib in this population and provide new insights on long-term responders. Interactive data visualization is available at the COLUMBUS dashboard (https://clinical-trials.dimensions.ai/columbus7/).
与维莫非尼相比,恩考芬尼联合比美替尼和恩考芬尼单药治疗 BRAF V600E/K 突变型转移性黑色素瘤患者可改善无进展生存期(PFS)和总生存期(OS)。我们报告了 COLUMBUS 第 1 部分(NCT01909453)7 年分析的结果,截至 99.7 个月(随机分组和数据截止之间的中位时间)。
577 例局部晚期不可切除或转移性 BRAF V600E/K 突变型黑色素瘤患者,既往未接受治疗或一线免疫治疗后进展,按 1:1:1 随机分组,分别接受恩考芬尼 450mg 每日一次(QD)联合比美替尼 45mg 每日两次(BID)(n=192)、维莫非尼 960mg BID(n=191)或恩考芬尼单药 300mg QD(n=194)治疗。不允许使用以前的 BRAF/MEK 抑制剂。
恩考芬尼联合比美替尼组 7 年 PFS 和 OS 率(95%CI)分别为 21.2%(14.7-28.4%)和 27.4%(21.2-33.9%),维莫非尼组分别为 6.4%(2.1-14.0%)和 18.2%(12.8-24.3%)。恩考芬尼联合比美替尼组黑色素瘤特异性生存(95%CI)中位数为 36.8 个月(27.7-51.5 个月),维莫非尼组为 19.3 个月(14.8-25.9 个月)。34 例长期应答者(7 年时持续完全/部分缓解)在各治疗组中被发现。
这是 BRAF V600E/K 突变型转移性黑色素瘤中 BRAF/MEK 抑制剂联合治疗的最长随访时间。安全性结果与恩考芬尼联合比美替尼已知的可耐受特征一致。结果支持恩考芬尼联合比美替尼在该人群中的长期疗效和已知安全性,并为长期应答者提供了新的见解。交互式数据可视化可在 COLUMBUS 仪表板(https://clinical-trials.dimensions.ai/columbus7/)上查看。